EMBC
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Rule-based valuation (P/E + Graham).
- Trades at attractive 3.7x trailing earnings.
Rule-based growth outlook.
- Growth-implied value exceeds price.
- Revenue is contracting.
Historical performance + price trend: Shares moved -78.3% over 5Y and -18.7% over 1Y.
- Insufficient data for clear positives.
Balance sheet & liquidity (Z-Score: N/A).
- Insufficient data for clear positives.
Dividend policy fallback.
- Moderate dividend profile (Score: 55/100).
- Yield: 6.7%.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for EMBC and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
EMBC
Embecta Corp.
Primary
|
-78.3% | -65.2% | -18.7% | -34.0% | -3.8% | +1.0% |
|
AVR
Anteris Technologies Global Corp.
Peer
|
-8.8% | -8.8% | +40.4% | +17.2% | -21.5% | -6.6% |
|
ANGO
AngioDynamics, Inc.
Peer
|
-49.3% | +20.9% | +23.6% | +7.9% | +5.1% | +6.4% |
|
BWAY
BrainsWay Ltd.
Peer
|
+163.4% | +1289.2% | +184.8% | +61.0% | -3.2% | -7.8% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-27.7% | +432.4% | +47.8% | -20.4% | +5.2% | -4.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
EMBC
Embecta Corp.
|
NEUTRAL | $525.87M | 3.73 | -% | 12.9% | $8.88 | |
|
AVR
Anteris Technologies Global Corp.
|
BEARISH | $496.86M | - | -301.9% | -% | $5.11 | Compare |
|
ANGO
AngioDynamics, Inc.
|
BEARISH | $492.14M | - | -15.3% | -9.0% | $11.94 | Compare |
|
BWAY
BrainsWay Ltd.
|
NEUTRAL | $490.8M | 68.11 | 11.3% | 14.6% | $12.26 | Compare |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $490.45M | - | -% | -188.1% | $4.02 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-11 | MORRIS MILTON MAYO | Director | Stock Award | 22,841 | - |
| 2026-02-11 | HOMBACH ROBERT J. CPA | Director | Stock Award | 22,841 | - |
| 2026-02-11 | PRANGE KAREN N. | Director | Stock Award | 22,841 | - |
| 2026-02-11 | POMEROY CLAIRE | Director | Stock Award | 22,841 | - |
| 2026-02-11 | ANDERSON CARRIE L | Director | Stock Award | 22,841 | - |
| 2026-02-11 | REIDY CHRISTOPHER R | Director | Stock Award | 22,841 | - |
| 2025-11-26 | CASNER JEAN | Officer | Stock Award | 38,783 | - |
| 2025-11-26 | MANN JEFFREY Z | General Counsel | Stock Award | 104,050 | - |
| 2025-11-26 | ELGUICZE JACOB | Chief Financial Officer | Stock Award | 125,613 | - |
| 2025-11-26 | KURDIKAR DEVDATT | Chief Executive Officer | Stock Award | 392,012 | - |
| 2025-11-26 | CURTIS SHAUN | Officer | Stock Award | 49,094 | - |
| 2025-11-26 | ROTH ANTHONY M. | Officer | Stock Award | 32,817 | - |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning EMBC from our newsroom.